Cue Biopharma (CUE) Common Equity (2017 - 2025)

Cue Biopharma has disclosed Common Equity across 9 years of filings, most recently posting $26.4 million for Q4 2025.

• Common Equity for Q4 2025 came in at $26.4 million, up 51.05% year-over-year; the trailing twelve-month figure through Dec 2025 was $26.4 million (up 51.05% YoY), and the FY2025 annual result was $26.4 million, up 51.05% from the prior year.
• Common Equity came in at $26.4 million for Q4 2025 at Cue Biopharma, up from $13.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $72.9 million in Q2 2021 to a low of $6.6 million in Q1 2025.
• The 5-year median for Common Equity is $44.3 million (2023), against an average of $42.6 million.
• Across the five-year window, Common Equity jumped 54.01% in 2021 and slumped 78.09% in 2025, its largest moves.
• Cue Biopharma's Common Equity stood at $65.5 million in 2021, then grew by 0.29% to $65.7 million in 2022, then sank by 43.54% to $37.1 million in 2023, then sank by 52.81% to $17.5 million in 2024, then soared by 51.05% to $26.4 million in 2025.
• The last three Common Equity figures came in at $26.4 million (Q4 2025), $13.2 million (Q3 2025), and $18.2 million (Q2 2025), per Business Quant data.